Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 3 5Phase 1/2 4Phase 1 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Thoracic 1Gynecologic 1Gastrointestinal 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 624pembrolizumab 500Paclitaxel 456Gemcitabine 438Carboplatin 435Cisplatin 418Radiotherapy 380fludarabine 365Nivolumab 340Docetaxel 277Bevacizumab 276Irinotecan 257Magnetic Resonance Spectroscopy 242Fluorouracil 228Dexamethasone 225Specimen Handling 221Capecitabine 218Rituximab 205Cytarabine 201Oxaliplatin 200Ipilimumab 199Temozolomide 197Biopsy 196fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 173Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Interventional × zanidatamab × Clear all
NCT05868226 2025-04-04

PRE-I-SPY-PI

QuantumLeap Healthcare Collaborative

Phase 1 Recruiting
124 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT02892123 2024-11-27

Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

Jazz Pharmaceuticals

Phase 1 Completed
279 enrolled
BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡